¡Ya estamos en ! Descubre más
CDAK

Codiak BioSciences

Dejó de cotizar

CDAK dejó de cotizar en bolsa el 4 de abril de 2023.

 

Acerca de: Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Empleados: 53

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre CDAK.

Gráficos de precios implementados con Lightweight Charts™